In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Review: Clinical Considerations & Payer Perspectives
Late October saw the annual gathering of oncologists and industry in Madrid for ESMO 2023, bringing with it a wave of new clinical results across cancers and a...